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The sodium potassium pump (Na/K-ATPase) ensures the electrochemical 
gradient of a cell through an energy-dependent process that consumes 
approximately one third of regenerated ATP. We report that the G protein-
coupled receptor GPR35 interacted with the α chain of Na/K-ATPase and 
promotes its ion transport and Src signaling activity in a ligand-independent 
manner. Deletion of Gpr35 increased baseline Ca2+ to maximal levels and 
reduced Src activation and overall metabolic activity in macrophages and 
intestinal epithelial cells (IECs). In contrast, a common T108M polymorphism in 
GPR35 was hypermorphic and had the opposite effects to Gpr35 deletion on 
Src activation and metabolic activity. The T108M polymorphism is associated 
with ulcerative colitis and primary sclerosing cholangitis, inflammatory diseases 
with a high cancer risk. GPR35 promoted homeostatic IEC turnover, whereas 
Gpr35 deletion or inhibition by a selective pepducin prevented inflammation-
associated and spontaneous intestinal tumorigenesis. Thus, GPR35 acts as a 
central signaling and metabolic pacesetter, which reveals an unexpected role 
of Na/K-ATPase in macrophage and IEC biology.   
Schneditz, Elias et al  Page 4 
Introduction 
 
Genetic studies of complex diseases have been highly successful in identifying 
disease-associated single nucleotide polymorphisms (SNPs), but discerning 
the biology responsible for these associations has proven to be a formidable 
challenge. Indeed, for only a handful of disease-associated SNPs have the 
underlying mechanisms been elucidated. These examples, however, have 
shed new light on disease pathogenesis and highlighted the importance of 
transitioning our knowledge from SNPs to the underlying biology responsible 
for altering disease risk. 
 
We were intrigued by a protein coding variant (rs3749171, leading to a T108M 
substitution) in the G protein-coupled receptor (GPCR) gene GPR35, which is 
associated with risk for primary sclerosing cholangitis (PSC) and ulcerative 
colitis (UC) across multiple ethnicities (1-4). One advantage of investigating 
coding variants is that they are much more likely to be causal than non-coding 
associations. 
 
GPCRs are a large family of receptors, with over 300 non-olfactory members, 
and yet in general they remain relatively poorly understood. For instance, the 
endogenous ligands for over 100 GPCRs remain unknown or disputed, and the 
basic biological function of the majority is unknown. Despite this, GPCRs have 
been the class of targets for which small molecule therapeutics have been most 
successfully developed, even though this extends only to a minority of GPCRs 
(5, 6). Several candidate ligands of GPR35 have been suggested, foremost the 
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tryptophan metabolite kynurenic acid (KYNA) (7) and the chemokine CXCL17 
(8). However, KYNA exhibits astounding species-dependent differences in 
potency, which is particularly low (EC50 >10–3 M) for human GPR35 (9, 10), and 
CXCL17 does not act as ligand in some experimental systems (11) and is a 
member of a family (chemokine receptors) that are not predicted to cluster with 
GPR35’s predicted core ligand binding domain (12). As such, both putative 
ligands remain disputed (5). Consistent with being associated with 
inflammatory diseases with high cancer risk, GPR35 is expressed in a tissue-
specific pattern, with high expression in myeloid and intestinal epithelial cells 
(IECs) (7) – cell-types implicated in both UC and PSC – and is also highly 
expressed in several cancers (13, 14). 
 
PSC and UC are chronic inflammatory conditions of the bile ducts and the large 
intestine, respectively. (15, 16) Both diseases have an extreme cumulative risk 
for the development of cancer (17, 18)  Although PSC and UC are both 
considered autoimmune diseases, a classification that is supported by strong 
genetic association signals within the MHC region (19-21), the mechanistic 
basis of these disorders remains poorly understood, and the basis for the 
excessive cancer association is particularly enigmatic. 
 
Here we discovered that GPR35 interacted with and promoted the activity of 
Na/K-ATPase, the central ion pump that maintains a cell’s electrochemical 
gradient. We reveal the mechanism by which the T108M mutation not only 
altered risk of UC and PSC, but also contributed directly to the cancer risk 
associated with these diseases. We showed that this Na/K-ATPase modulation 
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was ligand-independent. Furthermore, we demonstrated that the disease-
associated variant was hypermorphic and elicited an increase in Na/K-ATPase 
activity with profound consequences for cellular membrane potential, Ca2+ 
homeostasis, and metabolism. This increase in Na/K-ATPase activity directly 
activated the kinase Src, thereby altering signaling through unrelated receptors 
and increasing cell proliferation and tumor formation. Finally, we described a 
pepducin therapeutic that targeted GPR35 and protected mice from tumor 
formation, in a manner similar to genetic deletion of Gpr35, which could 





GPR35 deficiency increases cytoplasmic Ca2+ levels 
Kynurenic acid (KYNA) and CXCL17 have been reported to trigger GPR35 
activation in cells transfected with this receptor (9, 22). KYNA, CXCL17 and 
zaprinast (a phosphodiesterase inhibitor that is a GPR35 agonist (23)) elicited 
intracellular Ca2+ release, cAMP production, and inositol-trisphosphate (IP3) 
generation in murine bone marrow-derived macrophages (BMDMs), which was 
absent in Gpr35–/– BMDMs (Fig. 1, A to C). Further consistent with receptor 
activation, the small GTPase Rho was gradually activated by both KYNA and 
CXCL17 in wild-type BMDMs, but not in Gpr35–/– BMDMs (fig. S1a). KYNA also 
elicited transient activation of the small GTPase Rac-1 in wild-type, but not 
Gpr35–/– BMDMs (fig. S1a). Consistent with the important role of Rac-1 on the 
cytoskeleton, fluorescent phalloidin imaging demonstrated actin filament 
Schneditz, Elias et al  Page 7 
reorganization upon KYNA stimulation in wild-type, but not Gpr35–/– BMDMs 
(fig. S1b). CXCL17 and KYNA also elicited a concentration-dependent 
chemotactic response in wild-type, but not Gpr35–/– BMDMs (Fig. 1D). 
Together, these results confirm in a genetic model that KYNA and CXCL17 
trigger GPR35 signaling.  
 
However, we observed that cytoplasmic Ca2+ levels were greatly increased in 
Gpr35–/– compared to wild-type BMDMs (Fig. 1A). These resting levels in 
Gpr35–/– BMDMs were as high as the peak intracellular Ca2+ achieved in wild-
type BMDMs upon stimulation with KYNA, CXCL17, and zaprinast. In contrast, 
baseline cAMP and IP3 concentrations were indistinguishable between Gpr35–
/– and wild-type BMDMs (Fig. 1, B and C). We also observed increased baseline 
(meaning, ligand-independent) migration in Gpr35–/– compared to wild-type 
mouse embryonic fibroblasts (MEFs), although only wild-type MEFs 
demonstrated chemotaxis to KYNA and zaprinast (Fig. 1, E and F). Increased 
baseline migration was also observed in GPR35-silenced THP1 (a human 
macrophage cell line) compared to control-silenced cells (Fig 1G). Collectively, 
these data demonstrate that even without GPR35 ligands, the genetic deletion 
of Gpr35 induces a phenotype analogous to that observed following ligand 
stimulation, suggesting that GPR35 has a constitutive, ligand-independent 
function.   
 
GPR35 interacts with the α chain of Na/K-ATPase 
To better understand the constitutive function of GPR35, we sought to examine 
the interactome of GPR35, because GPCR function often depends on protein-
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protein interactions (24). To perform an unbiased proteomics survey for 
interaction partners, we used human embryonic kidney HEK293T cells 
transfected with human GPR35 cDNAs as baits that were engineered to 
express Strep or hemagglutinin (HA) tags at the C terminus. In two independent 
experiments, the most abundant peptide hit for tagged GPR35 mapped to 
Na/K-ATPase subunit α1 (Uniprot P05023 isoform 4; encoded by ATP1A1), and 
was not present in HEK293T cells transfected with tag only, or in mock-
transfected cells (table S1).  
We confirmed this interaction in HEK293T cells transfected with GPR35-HA by 
probing HA immunoprecipitates for ATP1A1 to detect endogenous protein (Fig. 
1H). Moreover, a band consistent with GPR35-HA was detected by 
immunoblotting for HA in ATP1A1 immunoprecipitates (Fig. 1H). In contrast to 
GPR35-HA, HA-tagged GPCRs CXCR2, CCR5 or P2Y12 did not co-
immunoprecipitate with ATP1A1 (Fig. 1H), indicating that the interaction 
between Na/K-ATPase and GPR35 was specific for this particular GPCR.  
 
Na/K-ATPase consists of a catalytic α subunit (encoded by 4 genes, ATP1A1 
to ATP1A4) and a regulatory β subunit (encoded by 4 genes, ATP1B1 to 
ATP1B4), which is important for the recruitment of the α subunit to the plasma 
membrane (25, 26). ATP1A1 is ubiquitously expressed and the main α chain of 
heterodimeric Na/K-ATPase, whereas other α chains exhibit a more restricted 
expression pattern (27, 28). We therefore asked whether GPR35-Na/K-ATPase 
interaction was restricted to the ATP1A1 isoform only. To address this question, 
we co-transfected HEK293T cells with Myc-tagged α1, α2, or α3 chains (α4 is 
only expressed in testis, where GPR35 is not present (26)) together with either 
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HA-tagged GPR35108T (a non-risk variant) or GPR35108M (a risk variant). HA 
immunoprecipitates for both GPR35108T-HA and GPR35108M-HA pulled down all 
three Na/K-ATPase α chains as detected by immunoblotting for Myc (Fig. 1I). 
Conversely, Myc immunoprecipitates for α chain constructs pulled down 
GPR35-HA variants (Fig. 1I). GPR35108T and GPR35108M co-
immunoprecipitated to a similar extent with the individual Na/K-ATPase α 
chains (Fig. 1I). These data suggested that GPR35 biochemically interacts with 
ATP1A1, ATP1A2, and ATP1A3 chains, and this interaction is not affected by 
the GPR35 risk variant. 
 
To confirm the intimate relationship of GPR35 and ATP1A1, we used photo-
bleaching confocal fluorescent resonance energy transfer (FRET) microscopy 
of HEK293T cells transfected with a full-length ATP1A1 tagged C-terminally in-
frame with Venus (ATP1A1-Venus) as the fluorescent donor, and a construct 
of full-length GPR35 tagged C-terminally in-frame with Cerulean (GPR35-
Cerulean) as the fluorescent acceptor. A FRET signal typically occurs when 
fluorescent donors and acceptors are closer than 100 Å. The fluorescence 
signals of GPR35, ATP1A1 and the control CCR5 were located to the plasma 
membrane (Fig. 1J), with FRET efficiency between GPR35 and ATP1A1 of 7% 
(Fig. 1K) consistent with a distance equivalent to approximately 75 Å. For 
comparison, FRET efficiency between GPR35-Venus and GPR35-Cerulean 
was 18% (65 Å). In contrast, no FRET signal above background was obtained 
with HEK293T cells transfected with the chemokine receptor CCR5-Cerulean 
(1%) or CXCR2-Cerulean (0.7%) together with ATP1A1-Venus (Fig. 1K). The 
FRET signal obtained with GPR35108T-Cerulean was similar from GPR35108M-
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Cerulean upon co-transfection with ATP1A1-Venus (Fig. 1K). Together these 
data establish an intimate spatial relationship between the α1 subunit of Na/K-
ATPase and GPR35, whether it is wild-type or the GPR35T108M variant. 
Furthermore, a close spatial relationship did not exist between GPR35 and 
either CXCR2 or CCR5, suggesting that the interaction between Na/K-ATPase 
and GPR35 is specific. 
 
GPR35 promotes Na/K-ATPase function 
Considering the spatial relationship between GPR35 and ATP1A1, we 
hypothesized that GPR35 affects Na/K-ATPase function in macrophages and 
intestinal epithelial cells. Na/K-ATPase (EC 3.6.3.9) is the ubiquitously present 
cation pump (‘sodium-potassium pump’), which is essential for maintenance of 
the electrochemical gradient across the plasma membrane (26, 28). We directly 
assessed Na/K-ATPase pump function through inductively coupled plasma 
mass spectrometry (ICP-MS) using Rubidium (85Rb+) uptake in BMDMs and 
the colonic epithelial cell line Caco2. 85Rb+ is a tracer ion for K+ at physiological 
concentrations of extracellular K+, which does not natively occur in biological 
systems (29). Macrophages exhibit different functional states, which can be 
approximated in vitro by differentiation under M0 (baseline), M1 (‘inflammatory’, 
IFNγ+LPS) and M2 (‘regenerative’, IL-4) conditions (30). Gpr35–/– BMDMs 
differentiated under M0, M1 and M2 conditions transported less 85Rb+ across 
the plasma membrane compared to their corresponding wild-type cells. 
Moreover, selective inhibition of Na/K-ATPase with ouabain (31) decreased 
85Rb+ uptake further, reaching similarly low levels in wild-type and Gpr35–/– M0, 
M1 and M2 macrophages (Fig. 2A). We next asked whether GPR35-dependent 
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regulation of Na/K-ATPase extended to other cells that highly express the 
receptor, such as intestinal epithelial cells (IECs). Indeed a 75% knock-down 
(fig S2a) of GPR35 mRNA expression by siRNA in Caco2 cells resulted in a 
15% reduction in 85Rb+ uptake compared to cells transfected with control siRNA 
(Fig. 2B). Similar to BMDMs, ouabain reduced 85Rb+ uptake to similarly low 
levels in GPR35-silenced and control Caco2 cells (Fig. 2B). Consistent with the 
effect of GPR35 on Na/K-ATPase function, the plasma membrane potential 
(Δψp) was reduced in Gpr35–/– compared to wild-type BMDMs (Fig. 2C). These 
data demonstrate that in macrophages and IECs, GPR35 promotes Na/K-
ATPase ion pump activity and thereby determines the electrochemical gradient 
across the plasma membrane.  
 
GPR35 sets resting intracellular Ca2+ by promoting Na/K-ATPase function 
Intracellular Ca2+ is critical for many signaling pathways and resting levels are 
controlled indirectly by the Na/K-ATPase (through the Na/Ca exchanger) (32). 
We therefore investigated whether GPR35 was involved in regulating this 
process. Cardiac glycosides such as ouabain or digoxin increase cardiac 
contractility by increasing intracellular Ca2+ through inhibition of Na/K-ATPase 
(33). Consistent with this effect, ouabain increased cytoplasmic Ca2+ in wild-
type BMDMs to levels similar to that observed in Gpr35–/– BMDMs at baseline 
(Fig. 2D). In contrast, direct inhibition of Na/K-ATPase with ouabain did not 
further increase cytoplasmic Ca2+ in Gpr35–/– BMDMs (Fig. 2D). These data 
show that GPR35 maintains low intracellular Ca2+ levels by stimulating Na/K-
ATPase. 
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We therefore hypothesized that absence of GPR35 may affect signaling 
through unrelated GPCRs that rely on triggering a Ca2+ response. The CCR5 
ligands MIP-1β and RANTES, the -adrenoreceptor agonist isoproterenol, the 
endocannabinoid anandamide and lysophosphatidic acid (LPA) triggered 
hardly any Ca2+ response in Gpr35–/– BMDMs, in contrast to the effect in wild-
type cells (Fig. 2E). The increase in resting Ca2+ to maximum levels appeared 
to be specific for Gpr35 deletion, because siRNA-mediated knock-down (fig 
S2b) of mRNAs encoding other, unrelated GPCRs such as Ccr5, Adrb2 (which 
encodes the 2-adrenoreceptor), cannabinoid receptor 2 (Cnr2), and LPA 
receptor 2 (Lpar2) in BMDMs did not affect, or minimally lowered resting 
intracellular Ca2+ (Fig. 2F). Together, these data indicate that Ca2+ signaling is 
altered in the absence of GPR35 due to decreased Na/K-ATPase function, 
which blunts signaling through unrelated GPCRs. 
 
The GPR35T108M polymorphism augments Na/K-ATPase activity  
The activity of Na/K-ATPase is controlled both transcriptionally and post-
translationally (25, 34, 35). We therefore investigated whether the effects of 
GPR35 deficiency might occur by regulating these processes. However, 
plasma membrane and intracellular pools of ATP1A1 (Fig. 2G) and total cellular 
ATP1A1 protein levels were similar between Gpr35–/– and wild-type BMDMs 
(Fig. 2H) and in colon epithelial scrapings (Fig. 2I). ATP1A1 phosphorylation, 
which has previously been associated with the recruitment of new pumps to the 
cell membrane (36, 37), was also not affected by Gpr35 genotype (Fig. 2, H 
and I). This finding suggested that the GPR35-dependent regulation of Na/K-
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ATPase was not mediated by transcription or post-translational control and thus 
that a protein-protein interaction might be involved. 
 
We reasoned that if regulation of Na/K-ATPase activity by GPR35 is the 
physiologically critical function of this GPCR, GPR35T108M would affect ion 
transport. The human induced pluripotent stem cell (iPSC) line HPSI0114i-
kolf_2 (‘KOLF2’) has been derived from a male individual of European descent 
and is homozygous for the protective C allele (encoding threonine at amino acid 
position 108). Using CRISPR/Cas9 gene editing, we introduced a single-
nucleotide mutation in multiple derivative KOLF2 iPSC lines (‘KOLF2-108M’) to 
make them homozygous for the risk allele (ATG instead of ACG). We 
differentiated the parent and derivative KOLF2 lines toward macrophages (38) 
and subjected them to 85Rb+ uptake assays. KOLF2-108M macrophages 
exhibited significantly increased 85Rb+ uptake compared to parental KOLF2 
macrophages (Fig. 2J), indicative of increased ion transport activity. Inhibition 
of Na/K-ATPase with ouabain decreased 85Rb+ uptake to similarly low levels in 
both cell lines (Fig. 2J). Consequently, basal intracellular Ca2+ levels were lower 
in KOLF-108M compared to KOLF-108T derived macrophages (Fig. 2K). 
Random migration of KOLF-108M macrophages was lower than of KOLF-
108T-derived cells (Fig. 2L). As expected, this phenotype was not associated 
with altered levels of ATP1A1 protein in KOLF-108M compared to KOLF-108T 
macrophages (Fig 2M). Hence, changes in 85Rb+ transport, baseline Ca2+ levels 
and random migration in T108M carrying cells were reminiscent of GPR35 
deficiency, demonstrating the hypermorphic nature of the GPR35T108M 
polymorphism. 
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GPR35 controls macrophage and intestinal epithelial cell metabolism 
Na/K-ATPase activity accounts for ~30% of a cell’s overall energy consumption, 
which in some cell types is preferentially fueled by ATP regenerated by aerobic 
glycolysis (25, 39-45). We therefore hypothesized that reduced Na/K-ATPase 
activity in the absence of GPR35 might lead to decrease demand for glucose. 
Glucose uptake was indeed profoundly reduced in Gpr35–/– BMDMs compared 
to wild-type cells, irrespective of polarizing condition (Fig. 3A). Inhibition of 
Na/K-ATPase with ouabain almost completely abrogated glucose uptake in 
both wild-type and Gpr35–/– BMDMs differentiated under M0 or M2 conditions, 
whereas ouabain proportionally decreased glucose uptake in Gpr35+/+ and 
Gpr35–/– M1 BMDMs (Fig. 3A). Correspondingly, the production of lactic acid, 
the end product of aerobic glycolysis, was lower in Gpr35–/– compared to 
Gpr35+/+ BMDMs (Fig. 3B). This finding demonstrated that GPR35 promoted 
glucose uptake and oxidation in a Na/K-ATPase-dependent manner. In IECs, 
GPR35-silenced Caco2 cells exhibited lower extracellular acidification rates 
(ECAR) (Fig. 3C), which is a measure of aerobic glycolysis in metabolic flux 
studies, thus indicating that GPR35 also promoted glycolysis in this cell type.  
 
Oxygen consumption rate (OCR), a measure of mitochondrial oxidative 
phosphorylation (OXPHOS) (46) was also reduced in Gpr35–/– M0 and M2 
BMDMs compared to wild-type BMDMs (Fig. 3d). Specifically, both basal and 
maximum OCR were lower in Gpr35–/– M0 and M2 BMDMs, whereas OCR was 
low in M1 BMDMs of either genotype (fig. S3) as expected (47). GPR35 also 
augmented OXPHOS in Caco2 cells as revealed through Gpr35 silencing (Fig. 
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3E). Consistent with impaired OXPHOS, mitochondrial membrane potential 
(ΔΨm) was reduced in Gpr35–/– M0 and M2 BMDMs compared to their Gpr35+/+ 
controls (Fig. 3F). This effect depended on Na/K-ATPase pump function, 
because ouabain reduced ΔΨm to similarly low levels as achieved by complete 
dissipation of the mitochondrial electrochemical proton gradient with FCCP 
(Fig. 3F). Together, these results showed that augmentation of Na/K-ATPase 
activity by GPR35 involved both aerobic glycolysis and also oxidative 
phosphorylation to meet energetic demands, highlighting the effect of this 
receptor on energy metabolism.  
 
We next sought to understand the effect of the disease-associated SNP on this 
effect. Glucose uptake in KOLF-108M-derived macrophages was increased 
compared to KOLF-108T cells (Fig 3G). Consistent with a higher energetic 
demand of KOLF-108M- compared to KOLF-108T-derived cells, macrophages 
exhibited a higher basal ECAR (Fig. 3H) and increased lactate production (Fig. 
3I). KOLF-108M-derived macrophages also exhibited increased baseline and 
maximum OCR compared to KOLF2-108T-derived cells (Fig. 3J). These data 
are consistent with the hypermorphic nature of the GPR35T108M variant and 
demonstrate that this variant increases energy demand because of increased 
Na/K-ATPase activity. 
 
GPR35 modulates Na/K-ATPase-dependent signaling 
Na/K-ATPase is also an important signaling scaffold because ATP1A1 binds a 
portion of cellular Src (25, 28, 48). Src is a member of the Src family non-
receptor protein tyrosine kinases and plays a critical role in signal transduction 
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of many extracellular stimuli such as cytokines, growth factors, and stress 
responses (49). Binding of cardiotonic steroids such as ouabain to Na/K-
ATPase activates Src (25, 50-54). We therefore assessed whether GPR35 
modulated basal Src activity in a Na/K-ATPase dependent manner. Indeed, 
Gpr35–/– BMDMs exhibited decreased phosphorylation of Src Tyr416 compared 
to Gpr35+/+ BMDMs (Fig. 4A). Phosphorylation at Tyr416 in the activation loop 
of the kinase domain activates Src and thereby induces down-stream signaling. 
(55). 
 
Na/K-ATPase-dependent activation of Src can transactivate the epidermal 
growth factor receptor (EGFR) and mitogen-activated protein kinases (MAPK), 
phospholipase C γ (PLC-γ) and the IP3 receptor, and phosphoinositol-3-kinase 
(PI3K) and Akt (25, 56-60). In Gpr35–/– BMDMs, phosphorylation of 
Thr202/Tyr204 of the MAPK extracellular signal-regulated kinases (ERK)1/2 was 
reduced compared to wild-type BMDMs (Fig. 4B). Phosphorylation of ERK at 
these residues fully activates the kinase (61). Phosphorylation of Akt Thr308 and 
Ser473 were absent and substantially reduced, respectively, in Gpr35–/– 
compared to wild-type BMDMs (Fig. 4C), suggesting lower glycolysis and less 
proliferative signaling in cells lacking GPR35. Baseline phosphorylation of Src 
and consequently Akt in wild-type BMDMs depended on the Na/K-ATPase – 
Src complex, because it was almost completely inhibited by pNaKtide (Fig. 4, 
D and E), a cell-permeable selective inhibitor of Na/K-ATPase-dependent 
activation of Src that does not affect cytoplasmic Src (62). Furthermore, 
pNaKtide did not further reduce the low levels of residual Src and Akt 
phosphorylation observed in Gpr35–/– BMDMs (Fig. 4DE). Consistent with 
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reduced Akt Thr308 and Ser473 in Gpr35–/– BMDMs, the phosphorylation of Thr172 
in 5'-adenosine monophosphate-activated protein kinase (AMPK) was 
increased in Gpr35–/– compared to wild-type BMDMs (Fig. 4F), indicating 
perturbed energy homeostasis in the absence of GPR35. Phosphorylation of 
AMPK at Thr172 which is located in the activation chain of its  subunit is 




The strong baseline phosphorylation of Tyr416 in Src in control-silenced Caco2 
IECs was almost absent in GPR35-silenced cells (Fig. 4G). Correspondingly, 
Akt Thr308 and Ser473 phosphorylation was reduced in GPR35-silenced Caco2 
compared to control-silenced cells (Fig. 4H). Furthermore, activating EGFR 
Tyr1068 phosphorylation was reduced in Caco2 cells with knock-down of GPR35 
compared to control cells (Fig. 4I). These results indicate that regulation of 
these phosphorylation events by GPR35 extended beyond macrophages to 
IECs. Furthermore, these data suggest that GPR35 maintains a baseline tone 
of Src activation by the Na/K-ATPase-associated plasma membrane pool of 
Src. GPR35 thereby determines the degree of baseline activation of cardinal 
signaling nodes such as Akt, ERK1/2, and EGFR. 
 
Human macrophages and fibroblasts differentiated from KOLF2-108M iPSCs 
displayed increased Src Tyr416 phosphorylation compared to their 
corresponding KOLF2-108T-derived cells (Fig 4, J and K). pNaKtide inhibited 
Src Tyr416 phosphorylation in both KOLF2-108M and KOLF2-108T iPSCs-
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derived macrophages (Fig. 4L), which demonstrated the involvement of Na/K-
ATPase in Src activation. Corresponding to increased Src Tyr416 
phosphorylation, ERK1/2 Thr202/Tyr204 and Akt Thr308 phosphorylation was 
increased in KOLF-108M- compared to KOLF-108T-derived macrophages and 
fibroblasts (Fig. 4, J and K). Collectively, these findings demonstrate that the 
GPR35 T108M risk variant that is associated with risk for UC and PSC 
augments Src, ERK1/2 and Akt signaling in a Na/K-ATPase-dependent 
manner. Hence, GPR35 modulation of Na/K-ATPase-dependent signaling 
extends to many cell types expressing this receptor, is conserved between 
species, and is independent of GPR35’s cognate ligand(s).  
 
GPR35 maintains IEC turn-over under homeostatic conditions 
EGFR/Src−Ras−ERK and PI3K1A−PDK−Akt signaling are critically involved in 
proliferation of many cell types (57-60, 66). The intensity of immunostaining for 
phospho-Tyr416 Src was reduced in the intestinal epithelium of Gpr35–/– 
compared to that of wild-type mice (Fig. 5A), consistent with our observations 
in Caco2 cells (Fig. 4G). Hence we investigated the role of GPR35 in the 
baseline turn-over of IECs. The number of IECs that had migrated along the 
crypt-villous axis after a 24h pulse of BrdU was reduced by more than 50% in 
Gpr35–/– compared to wild-type mice (Fig. 5B). This effect corresponded to a 
comparable decrease in the number of IECs staining for the proliferation marker 
Ki-67 in Gpr35–/– compared to wild-type mice (Fig. 5C). Colonic intestinal 
organoids derived from Gpr35–/– mice exhibited similarly decreased 
proliferation as determined by fewer cells incorporating EdU compared to 
cultures derived from wild-type mice (Fig. 5D). These data demonstrated a 
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~40% reduction in the turn-over of the intestinal epithelium in the absence of 
GPR35. Moreover, administration of pNaKtide (67) resulted in a reduction in 
IEC turn-over in wild-type mice to levels observed in vehicle-treated Gpr35–/– 
mice, whereas pNaKtide did not cause any further reduction in GPR35-deficient 
mice (Fig. 5E). Together, these data identify a Na/K-ATPase–Src-dependent 
mechanism through which GPR35 promotes the homeostatic renewal of the 
intestinal epithelium. 
 
Loss of GPR35 protects from intestinal tumorigenesis 
Based on the effects of GPR35 on IEC turnover, we hypothesized that GPR35 
might also affect intestinal tumor development. We crossed Gpr35–/– mice with 
Apcmin mice, which carry a hypomorphic variant of Apc, whose human 
orthologue APC causes adenomatous polyposis coli and is a major early driver 
of spontaneous colorectal cancer (CRC) (68, 69). Gpr35–/–;Apcmin mice 
developed 40% fewer intestinal tumors (namely non-invasive adenomas), 
compared to Apcmin mice with intact GPR35 (Fig. 6A), indicating that GPR35 
plays an important role in intestinal tumor promotion. GPR35 is highly abundant 
in IECs. Furthermore Gpr35 mRNA expression was significantly higher in 
tumors compared to healthy intestinal tissue (Fig. 6B). We hence predicted an 
IEC-intrinsic role of GPR35. We therefore generated mice with a floxed Gpr35 
allele (‘Gpr35flox’), and crossed them with IEC-specific Cre recombinase 
transgenic mice (‘Vil-Cre’) (70) and the Apcmin line to obtain Vil-
Cre;Gpr35flox/flox;Apcmin mice (‘Gpr35ΔIEC;Apcmin’) and Vil-Cre-negative GPR35-
wild-type littermates (‘Gpr35WT;Apcmin’). Gpr35 mRNA expression was 
significantly reduced or not detectable in Gpr35ΔIEC mice (Fig 6C). At week 15, 
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Gpr35ΔIEC;Apcmin mice had developed 30% fewer tumors compared to 
Gpr35WT;Apcmin mice (Fig. 6D). Correspondingly, the percentage of proliferative 
cells staining positive for Ki-67 were significantly lower in Gpr35ΔIEC;Apcmin 
compared to Gpr35WT;Apcmin mice (Fig. 6E). 
 
In contrast to sporadic CRC, APC mutations are less common in colitis-
associated cancer (CAC), which is instead characterized by field cancerization 
and a distinct mutational spectrum (71-73). CAC can be modelled in mice by 
administration of the carcinogen azoxymethane (AOM) followed by 3 cycles of 
the barrier-breaching chemical dextran sodium sulfate (DSS) (74, 75). Gpr35–
/– mice subjected to AOM-DSS developed 35% fewer colorectal tumors 
compared to littermate wild-type and Gpr35+/+ mice (Fig. 6F). Together, these 
data demonstrate that GPR35 promotes intestinal tumorigenesis in both, 
spontaneous and inflammation-driven tumor models.  
 
Pharmacological targeting of GPR35 selectively modulates receptor activity 
Short lipid-coupled peptides (‘pepducins’) with sequence identity to intracellular 
loops can selectively activate or inhibit GPCRs as has been demonstrated for 
several classes of G protein coupled receptors (76). The GPR35T108M 
polymorphism and adjacent DRY motif are close to the i2 loop of GPR35 (Fig. 
7A). We therefore designed a series of palmitoylated peptides that targeted the 
i1, i2, or i3 loop and initially screened them in wild-type compared to Gpr35–/– 
BMDMs for their effect on Ca2+ and chemotactic responses (fig S4, A and B). 
g35-i2 and g35-i3, which target the i2 and i3 loop, respectively, were 
characterized further (Fig. 7A). g35-i2 triggered a transient increase in IP3 in 
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wild-type BMDMs, which was absent in Gpr35–/– BMDMs (Fig. 7B). Similarly, 
g35-i3 triggered cAMP production (Fig. 7C), and transient Rac-1 and RhoA 
activation (Fig. 7D) in wild-type, but not in Gpr35–/– BMDMs. Both pepducins 
increased intracellular Ca2+ over time in wild-type BMDMs, which reached the 
higher baseline Ca2+ levels in Gpr35–/– cells, without affecting intracellular Ca2+ 
in Gpr35–/– cells (Fig. 7E). g35-i2 and g35-i3 were active across species 
because both induced a chemotactic response in human THP1 cells 
transfected with control siRNA, but not in those transfected with GPR35 siRNA, 
hence demonstrating specificity (Fig. 7F). To assess whether g35-i2 could 
modulate the response to known agonists, we pre-incubated THP1 cells with 
pepducin before adding KYNA, CXCL17 and zaprinast. g35-i2 blocked 
migration to these agonists in control-silenced, but not in GPR35-silenced 
THP1 cells (Fig. 7G). We were interested to explore whether pepducins would 
affect Na/K-ATPase-dependent ion transport. Indeed, g35-i2 reduced ouabain-
inhibitable 85Rb+ transport in wild-type BMDMs to levels similar to those in 
untreated Gpr35–/– BMDMs, whereas no further reduction in 85Rb+ transport 
was detected in Gpr35–/– BMDMs when incubated with g35-i2 (Fig. 7H). In 
contrast, KYNA or Zaprinast did not affect 85Rb+ uptake in wild-type BMDMs, 
and the difference in ion transport between wild-type and Gpr35–/– cells was 
maintained in KYNA-treated cells (Fig. 7H). Zaprinast increased 85Rb+ uptake 
in Gpr35–/– BMDMs (Fig. 7H), an effect that may be related to its promiscuity 
and clinical use as a phosphodiesterase inhibitor (23). Together, these data 
show that g35-i2 inhibits Na/K-ATPase ion transport function, which 
distinguishes this agonist from previously reported GPR35 agonists. 
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g35-i2 decreases tumor burden in colitis-associated cancer 
We next investigated whether g35-i2 and g35-i3 would affect homeostatic turn-
over of IECs in vivo. Intraperitoneal administration of either pepducin reduced 
BrdU+ cells along the crypt-villus axis after a 24h pulse of BrdU in wild-type 
mice to levels observed in vehicle-treated Gpr35–/– mice (Fig. 7I). In contrast, 
g35-i2 and g35-i3 did not affect IEC turn-over in Gpr35–/– mice (Fig. 7I), thereby 
also demonstrating specificity of these pepducins in vivo. Finally, we chose the 
g35-i2 pepducin to explore GPR35 as a pharmacological target in CAC. Wild-
type and Gpr35–/– mice undergoing the AOM/DSS model were administered 
g35-i2 intraperitoneally, starting with the first cycle of DSS. g35-i2 reduced 
tumor numbers by 57.4% in wild-type mice, which is a reduction similar to that 
observed in vehicle-treated Gpr35–/– mice (Fig. 7J). In contrast, no additional 
decrease was observed in g35-i2-treated Gpr35–/– mice (Fig. 7J). Thus, 





Here we identified GPR35 as a key promoter of Na/K-ATPase ion pumping 
function and Src signaling activity. This property did not apply to other GPCRs 
we tested and did not require cognate ligand engagement. It appeared to be 
distinct from canonical signaling that is triggered by the proposed agonists of 
GPR35. These ligand-independent GPR35 activities on Na/K-ATPase function 
were enhanced with the disease risk-associated GPR35T108M variant. GPR35-
dependent alterations in Na/K-ATPase ion pump function re-set baseline 
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intracellular Ca2+ levels; in the absence of GPR35, baseline Ca2+ levels were 
increased to levels otherwise only observed upon receptor triggering, whereas 
baseline Ca2+ levels were lowered with the GPR35T108M variant. Through Na/K-
ATPase, GPR35 also set baseline Src kinase activity, which was lowered in the 
absence of GPR35, and increased by the GPR35T108M variant. Consequently, 
signaling induced by various ligands unrelated to GPR35 that trigger Ca2+ and 
Src activation were affected by GPR35. 
 
We showed that through these mechanisms, GPR35 potently promoted 
intestinal epithelial turnover and intestinal tumourigenesis. Elegant studies in 
Drosophila and mice with conditional epithelial deletion has revealed that Src 
drives intestinal stem cell proliferation through upregulation of EGFR and 
activation of Ras/MAPK and Stat3 signaling (66). Although mammalian SFKs 
Src, Fyn and Yes are redundant for intestinal homeostasis, Src has a non-
redundant role in damage-induced intestinal regeneration (66, 77). Compared 
to normal epithelium, Src expression is increased in ~80% of human CRCs and 
associated with poor prognosis (78, 79), and putative activating Src mutations 
are common (80). In addition to its long-appreciated role in advanced tumor 
stages and metastasis (81), Src is also required for early intestinal 
tumorigenesis caused by APC mutation (66), which may be of particular 
importance in the tumor-prone epithelium in UC and PSC. Nonetheless, the 
protective effect of Gpr35 deletion in the CRC Apcmin and the AOM/DSS CAC 
model was likely not only a consequence of reduced Na/K-ATPase-dependent 
Src signaling, but may also be determined by an altered Ca2+ signaling 
threshold and reduced metabolic activity present in GPR35-deficient intestinal 
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epithelium. In this context, GPR35-related activation of Akt, which plays an 
evolutionarily conserved role in cellular metabolism, proliferation, and cell 
survival (82), may similarly contribute to the tumor-promoting ability of GPR35. 
 
Direct protein-protein interaction is important in regulating Na/K-ATPase activity 
although the precise mechanisms remain mostly unresolved and diverse 
domains within ATP1A1 have been implicated (25) (83) (84). It will be important 
to elucidate the structural basis of Na/K-ATPase modulation by GPR35, 
including its mode of tonic activation of Src. Finally, it remains conceivable that 
endogenous GPR35 ligands, different from those that induce canonical 
signaling, may exist that modulate GPR35’s Na/K-ATPase-promoting activity. 
 
Targeting GPR35 therapeutically might therefore be attractive, especially in 
patients at high risk for cancer such as in UC and PSC, in which GPR35T108M is 
the strongest genetic risk factor outside the MHC. Here we characterized 
GPR35-specific pepducins that blocked both agonist-triggered GPR35 
activation and also GPR35-mediated promotion of Na/K-ATPase ion transport 
and signaling activity. In contrast to agonist or antagonist binding to the 
orthosteric binding pocket of GPCRs, pepducins translocate across the cell 
membrane and target the intracellular surface of the receptor (76, 85, 86). 
Pepducins can allosterically modulate receptor signaling and can also function 
in a biased manner to selectively promote the interaction with specific G 
proteins over others, G protein receptor kinases, and β-arrestins (76, 87, 88), 
although the precise mechanism of action remains unclear. The effect of g35-
i2 on Na/K-ATPase suggests that pepducins may also block the interaction of 
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GPCRs with transmembrane proteins. A first-in-human study of a pepducin 
(PZ-128) has shown promising results for proteinase activated receptor 1 
(PAR1) blockade in acute coronary syndrome (89). In conclusion, studying in-
depth a single ‘risk gene’ of two complex inflammatory diseases that are tumor-
prone, we discovered a GPCR that directly promotes a fundamental process of 
a cell, established hypermorphic function of the variant associated with disease 
risk, characterised its implications for tumor biology, and developed a candidate 
therapeutic that is effective in vivo.  
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Materials and Methods 
Mice 
Ear-biopsy genomic DNA was used for routine genotyping of all mice. All mice 
were bred and maintained in specific pathogen-free conditions at the Central 
Biomedical Services (CBS) facility, University of Cambridge. All procedures 
performed in studies involving animals were in accordance with the ethical 
standards of the institution or practice at which the studies were conducted and 
all were conducted with approval of the UK home office. Gpr35-/- mice were 
obtained from the KOMP repository (clone ID 646854). Conditional knock-out 
mice were generated by outbreeding the FlpO recombinase mice and then 
breeding in VillinCre transgene positive mice. Mice littered at Mendelian ratios 
and developed normally without any spontaneous disease emerging under 
specific pathogen free conditions. Six- to twelve-week-old mice that were age 
and sex matched as described in the relevant methods sections were used for 
all experiments unless otherwise stated.  
 
ApcMin/+ model of sporadic colon cancer 
ApcMin/+ mice were obtained from the Jackson Laboratory and intercrossed 
with mice lacking Gpr35 globally or conditionally in their intestinal epithelial 
cells. At the age of 15 weeks mice were sacrificed and after flushing with PBS 
the intestine was longitudinally cut, formalin fixed and tumor count was 
assessed microscopically. Samples were embedded as swiss rolls in either 
paraffin or OCT for further analysis. 
 
AOM/DSS model of colitis associated cancer 
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6-8-wk-old mice were injected intraperitoneally with 12.5 mg/kg AOM (Sigma-
Aldrich). Colitis was induced by two cycles of 2.5% DSS (MP Biomedicals) in 
drinking water for 5 days, followed by a 16 day tap water period (75). The final 
DSS cycle (2%) was administered for 4 days, followed by a 10 day tap water 
period. Tumor count and tumor area were determined at day 61 microscopically 
in longitudinally cut and formalin fixed specimen. 
 
Murine colonic crypt derived organoids 
The colon was flushed with cold PBS, cut longitudinally and into 5 mm pieces. 
To dissociate the crypts, pieces were placed in 25mM EDTA/PBS for 1h under 
constant gentle shaking at 4°C. Samples were washed multiple times with cold 
PBS followed by centrifugation at 1000 rpm. Isolated crypts were washed, 
counted and pelleted. A total of 200 crypts were mixed with 40 μl of Matrigel 
(Corning 354230) and plated in 24-well plates. After polymerization of Matrigel, 
500 μl of IntestiCult Organoid Growth Medium (Stem Cell #06005) containing 
100 ng/ml Wnt-3a (Peprotech 315-20) was added. Medium was changed every 
3 days. For passaging, organoids were removed from Matrigel and 
mechanically dissociated into single-crypt domains, then transferred to fresh 
Matrigel. Passaging was performed once per week with a 1:2 split ratio. 
 
EdU staining 
For EdU incorporation, 40 μl of matrigel containing organoids was seeded in 8-
well chamber-slides. 10 μM EdU was added to the wells 6 h prior to fixation. 
The proliferation marked by Edu incorporation was detected with Click-iT Edu 
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2.5 mg BrdU was injected i.p 24 h before euthanizing mice. Paraffin embedded 
samples were then de-paraffinised in xylene and de-hydrated with ethanol. 
Cells positive for BrdU were detected using a BrdU In-Situ Detection Kit (BD 




Crispr/Cas9 editing of human iPSC line 
The rs3749171 mutation in the human GPR35 gene was generated by a single 
base substitution (C>T) using CRISPR/Cas9-induced homology directed repair 
in the KOLF2 human iPSC line. This was achieved by nucleofection of 106 cells 
with Cas9-crRNA-tracrRNA ribonucleoprotein (RNP) complexes. Synthetic 
RNA oligonucleotides (target site: 5’- CCTGGTCACGGCCATCGCCG -3’ or 5’ 
CACATAGCGGTCCACGGCGA 3’, 225 pmol crRNA/tracrRNA) were annealed 
by heating to 95 C for 2 min in duplex buffer (IDT) and cooling slowly, followed 
by addition of 122 pmol recombinant eSpCas9_1.1 protein (in 10 mM Tris-HCl, 
pH 7.4, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT), incubation at room 
temperature for 20 minutes, and addition of 500 pmol of a 100 nt ssDNA 
oligonucleotide (IDT Ultramer) as a homology-directed repair template to 
introduce the desired base change. After recovery, plating at single cell density 
and colony picking into 96 well plates, 480 clones were screened for 
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heterozygous and homozygous mutations by high throughput sequencing of 
amplicons spanning the target site using an Illumina MiSeq instrument. Final 
cell lines were further validated by Sanger sequencing. Two independently 
targeted clones homozygous for 108T or 108M were used in downstream 
assays. 
 
Bone marrow derived macrophages (BMDMs) 
Mouse femurs and tibias were flushed with macrophage culture medium 
(RPMI-1640 containing 100 U/mL of penicillin-streptomycin, 1 mM HEPES pH 
7.4 and 10% FBS) and the bone marrow was filtered through a 70 μm cell 
strainer. Cells were thereafter incubated in macrophage culture medium 
supplemented with M-CSF (100 ng/mL) for 6 days. BMDMs were the reseeded 
and polarized overnight toward M1 or M2 with IFN-γ (50 ng/mL) plus LPS (20 
ng/mL) or with IL-4 (20 ng/mL), respectively. 
 
iPSC culture and macrophage differentiation 
The KOLF-2 human induced pluripotent stem cell line was maintained in 
mTeSR-E8 medium (Stemcell Technologies cat# 05990) on Vitronectin 
(rhVTN-N) coated plates (Gibco #A14700). For macrophage differentiation, 
pluripotent colonies were lifted using ReLeSR (Stemcell Technologies 
cat#05872) and plated onto irradiated MEFs on gelatin coated 100 mm tissue 
culture plates in Advanced DMEM-F12 (ThermoFisher Cat#12634028), 20% 
knock-out serum replacement (Gibco #10828028), 1% L-glutamine, 1% 
Penicillin/streptomycin and 7 μl/L 2-mercaptoethanol supplemented with 4 
ng/mL rhFGF basic (R&D systems Cat#233-FB-025). Once colonies were large 
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but not touching each other, they were lifted using 1mg/ml collagenase type IV 
(Gibco #17104-019) and 1 unit/mL dispase II (GIbco #17105-041) diluted in a 
1:1 ratio in Advanced DMEM-F12. Detached colonies were gently added to a 
15 mL tube using a 10 mL pipette to avoid breaking them up and were 
centrifuged at 300G for 3 minutes. After removing the supernatant, the colonies 
were gently re-suspended in fresh Advanced DMEM-F12 to wash and re-
centrifuged. This wash step was carried out a total of three times. Colonies 
were then transferred to non-adherent 100mm plates in 13ml of Advanced 
DMEM-F12 (ThermoFisher Cat#12634028), 20% knock-out serum 
replacement (Gibco #10828028), 1% L-glutamine, 1% Penicillin/streptomycin 
and 7μl/L 2-mercaptoethanol without FGF. After four days embryoid bodies had 
formed and these were collected in suspension, centrifuged and then plated in 
gelatin coated plates in X-Vivo-15 media (Lonza #BE02-060Q), 1% L-
glutamine, 1% Penicillin/Streptomycin and 7μl/L 2-mercaptoethanol 
supplemented with 50 ng/mL human M-CSF and 0.5 mg/mL IL-3. Media was 
changed twice weekly. After 20-30 days macrophage precursors began to 
appear in the media and were collected in suspension, strained using a 40 μm 
cell strainer and plated on standard tissue culture plates in RPMI 1640, 10% 
FBS and 1% L-glutamine supplemented with 100 ng/mL M-CSF. After 7 days, 
mature macrophages were used for assays. 
 
iPSC derived intestinal organoids 
The KOLF-2 human induced pluripotent cell line was differentiated into 
intestinal organoids as previously described (90). Organoids were maintained 
in Matrigel as spheroids and passaged every 5-7 days for a minimum of 10 
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passages to allow maturation before being used in assays. For protein 
extraction, organoids were removed from matrigel by mechanical dissociation 
in cold cell recovery solution (Corning #354253). The suspension was 
transferred to a 15 mL tube and incubated on ice for 30 minutes. The 
suspension was then centrifuged and the pellet resuspended in 1 mL cold cell 
recovery solution. After a further centrifugation, the pellet was resuspended in 
cold PBS and transferred to a 1.5 mL microcentrifuge tube before being 
centrifuged at 20,000 G for 3 mins. The pellet was then resuspended in 80 µL 
10mM Tris, 1% SDS, pH 7.4 supplemented with protease and phosphatase 
inhibitors. This resuspension was then incubated at 95 C for 30 mins before 
being sonicated for 5 seconds. Samples were then centrifuged and the 
supernatant used for western blotting. 
To culture the organoids in a monolayer, tissue culture plates were first coated 
with 0.5% (v/v) Matrigel in Advanced DMEM F12 medium for 1 hour at 37 C. 
Organoids were then released from Matrigel and broken into fragments by 
mechanical dissociation in ice cold PBS. The suspension was then centrifuged 
at 300 G for 3 mins before being resuspended and incubated in TrypLE Express 
(Gibco #12605036) for 10 mins at 37 C with intermittent gentle agitation to avoid 
clumping. The single cell suspension was then centrifuged and resuspended in 
organoid growth media before being counted and seeded. 
 
Intracellular Ca2+ assaysIntracellular Ca2+ was measured in BMDMs using 
Fluo-8 Calcium Flux Assay Kit (ABCAM, ab112129). In brief macrophages were 
incubated with inactive calcium dye which gets activated after penetrating the 
cell membrane. When active the dye binds to calcium released from the 
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endoplasmatic reticulum and fluorescence was measured in a fluorescent plate 




IP3 accumulation in macrophages was measured using the HitHunter® IP3 
Fluorescent Polarization Assay (GE Healthcare, 90-0037-02). M0 
macrophages were cultured in RPMI1640 containing 10% FBS and 100 ng/mL 
M-CSF, serum starved overnight and a series of different concentrations 
potential endogenous agonists were added to designated wells in a 96 well 
plate. The reaction was quenched after 1 minute and the tracer was added 
followed by an IP3 binding protein. Fluorescence was excited with a wavelength 
of 483 nm and emission was measured at 530 nm.  
 
cAMP assay  
Production of cAMP was measured using the cAMP-Glo Assay (Promega, 
V1501). In brief, 4 104 macrophages were seeded per well in a 96 well plate. 
Cells were treated with test compounds for the indicated time prior to lysis and 
detection of luminescence in a plate format luminometer. Values are given as 
relative luminescence units (RLU). 
 
Rac1- and RhoA G-LISA activation assays 
Overnight serum-starved BMDMs were exposed to test compounds for 5 sec, 
30 sec, 5 min, 30 min and 60 min. Thereafter cells were immediately lysed in 
ice-cold lysis buffer containing protease inhibitors, sodium fluoride, sodium 
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pyrophosphate, p-nitrophenyl phosphate and microcystin LR and G-LISA 
assays were performed according to the manufacturer’s instructions. Plates 
were read at 490 nm and values are given as extinction coefficient. 
 
Migration and chemotaxis in vitro assays 
Migration was measured in 48 well micro Boyden chambers equipped with a 5 
µm–pore-size cellulose nitrate filter which separated the upper and the lower 
chambers (Neuroprobe, Gaithersburg, MD). BMDMs were resuspended in 
RPMI 1640, 0.5% BSA (1x106 cells/mL). After a migration period of 4 h, the 
nitrocellulose filters were dehydrated, fixed, and stained with hematoxylin. The 
migration depth of the cells into the filters was quantified by microscopy, 
measuring the distance (in micrometers) from the surface of the filter to the 
leading front of three cells. Data are expressed as a chemotaxis index, which 
is the ratio between the distance of directed migration and random migration of 
monocytes into the nitrocellulose filters. 
Alternatively, THP1 cell migration was assessed using the Neuroprobe 
ChemoTx system (Neuroprobe, Gaithersburg, MD). THP1 cells were loaded 
with calcein-AM and then migrated towards pepducins or chemokines in the 
lower wells of the chamber. In inhibition experiments, THP1 cells were pre-




Cells were fixed with 4% paraformaldehyde containing either 0.2% or 1% Triton 
X-100 for 15 min at 20 °C or 100% methanol at −20 °C for 15 min. Fixed cells 
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or deparaffinised slides were washed with PBS and non-specific binding was 
blocked with either 5% normal serum or 0.5% milk before incubation with 
primary antibodies for 1 h at 20 °C. Unbound antibody was removed by washing 
with PBS and secondary antibody was bound for 30 min at 20 °C or overnight 
at 4 °C. Coverslips were then mounted with Prolong mounting media containing 
DAPI. Fluorescence was visualized with a Leica SP5 confocal microscope. 
 
Fluorescence resonance energy transfer (FRET) 
For construction method of vectors encoding C-terminal Cerulean (Addgene 
#27795) or Venus (Addgene #27793) fluorescent protein tagged versions of 
GPR35-T108T, GPR35-T108M, ATP1A1, CCR5 and CXCR2 see Section 
Cloning and Constructs. 24 hours prior to transfection, HEK293T cells were 
seeded onto Poly-L-Lysine coated glass coverslips in 6-well plates at a density 
of 0.5 x 106 per well. 2500 ng plasmid DNA was transfected using 
Lipofectamine 2000 (ThermoFisher #11668027) in Opti-MEM Reduced Serum 
Media (ThermoFisher 31985062) according to the manufacturer’s protocol. 
Pairs of different constructs were mixed 1:1 prior to transfection. 24 hours post-
transfection, cells were washed with PBS and fixed with 4% paraformaldehyde 
in 0.12 M sucrose for 15 minutes, followed by three further PBS washes. 
Coverslips were then lifted and mounted onto microscope slides. FRET 
measurements were performed using a Leica TCS SP5 confocal microscope 
(Leica Biosystems) and Leica Application Suite Advanced Fluorescence 
software. FRET measurements were taken using the acceptor photobleaching 
method. Briefly, cells expressing similar fluorescence levels of both transfected 
constructs were identified. Baseline cerulean “donor” emission was measured 
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during excitation at 405nm wavelength at 10% laser power. The venus 
“acceptor” protein was then photobleached using 20 pulses of 514nm 
wavelength at 98% laser power so that it was no longer able to accept energy 
from the cerulean “donor”. The cerulean emission during excitation at 405nm 
wavelength at 10% laser power was then re-measured. FRET efficiency was 
then calculated from pre- and post-photobleaching emission values. 




Murine bone marrow derived macrophages and iPSC derived macrophages 
were plated in 96 well plates at a density of 50,000 cells per well. After 24 hours 
media was removed and replaced with 100 μL per well of RPMI, 1% L-
glutamine, 1% Penicillin/Streptomycin and 10% dialysed FBS (Gibco 
#26400044). At set timepoints, 5 μL of media was then sampled and diluted in 
95 μL PBS. Lactate concentration was measured using the Lactate-Glo Assay 
(Promega, J5021) according to the manufacturer’s instructions. 
 
Immunohistochemistry 
Paraffin sections were pre-treated with xylene and dehydrated in ethanol. 
Antigen retrieval was performed using citrate or EDTA buffer for 15 min at sub-
boiling temperature in a microwave, followed by blocking of endogenous 
peroxidases activity. Primary antibody was incubated overnight at 4°C and 
secondary biotinylated antibody was detected with streptavidin-HRP (Vector 
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BMDMs were seeded in V-well plates, centrifuged at 600 g 6 min and 
supernatant removed. Cells were then incubated with Fc-Block in FACS buffer 
for 15 min followed by incubation with the primary antibody (ATP1A1) in 50 µL 
FACS buffer for 1 hour at 4°C. Cells were then fixed in 2% paraformaldehyde 
for 10 min at RT. Cells were then permeabilised and incubated for 15 min at 
RT. At this point primary antibody was added for cytoplasmic staining for 1 hour 
4°C. Secondary antibody was added in 50 µL FACS buffer for 1 hour 4°C. Cells 
were then resuspended in FACS buffer and measured using BD Biosciences 
FACSCantoII. 
 
RNA extraction and RT-qPCR 
RNA was isolated using the RNeasy Mini kit (QIAGEN). RNA was then reverse 
transcribed with M-MLV RT (Invitrogen), and SYBR-Green (Eurogentec) qPCR 
was performed using MX-3000 (Agilent Technologies). Target gene expression 
is expressed as ratio to housekeeping gene expression. For oligonucleotide 
sequences, see table S2. 
 
Western blotting 
Cells were lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, and 0.1% SDS). Protein content was then 
tested using the BCA assay (Pierce) and equal amounts of lysates were boiled 
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in Laemmli buffer for 10 min at 95°C. Samples were then subjected to SDS-
PAGE. After blotting onto Hybond-P polyvinylidene fluoride membranes (GE 
Healthcare) blots were blocked with 5% milk in TBS-T, and primary antibody, 
in 5% BSA in TBS-T was added at 4ºC overnight. The protein was then detected 
by using a HRP-conjugated secondary antibody and visualized with LumiGLO 
(Cell Signaling Technology). 
 
Cloning and Constructs 
The Human GPR35a CDS was obtained from RefSeq entry NM_005301. 
Primers with EcoRI and BamHI (1 and 2 in table S2, respectively) linker 
sequences were used to amplify the GPR35 coding sequence from human 
cDNA. After double digestion of the resulting PCR fragment with EcoRI and 
BamHI, the DNA was cloned into the pEXPR-IBA103 human expression vector 
(IBA Life Sciences, Goettingen, Germany). This resulted in a C-terminal 
TwinStrep-tagged GPR35 expression system. 
We generated an identical construct for the GPR35aT108M variant through 
site-directed mutagenesis. First, two overlapping PCR fragments were 
generated using the mutagenic primers separately (3 and 4 in table S2), 
combined with the previously mentioned EcoRI/BamHI linker primers (1 and 2 
in table S2) respectively. In a second step, full length GPR35a coding sequence 
was generated with the linker primers (1 and 2 in table S2) only. The resulting 
fragment was cloned into pEXPR-IBA103. 
Constructs for FRET experiments were generated using vector backbones 
mVenusN1 and mCeruleanN1 that were a gift from Steven Vogel (Addgene 
plasmids #27793 and 27795). We generated GPR35a and GPR35aT108M 
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PCR fragments with EcoRI/BamHI linker sequences using the primer pair 5 and 
6 (table S2) for C-terminal fusion. Resulting PCR fragments and vector 
backbones were digested with EcoRI/BamHI. ATP1A1 cDNA (RefSeq entry 
NM_000701.7) was amplified using the primer pair 7 and 8 (table S2) for C-
terminal fusion. PCR fragments of ATP1A1 were cloned after XhoI/XmaI 
digestion. CXCR2 cDNA was amplified using primers 9 and 10 (table S2) and 
CCR5 using primers 11 and 12 (table S2). Both cDNAs were cloned after 
XhoI/HindIII digestion. We used N-terminal HA-tagged expression vectors for 
GPR35 (#GPR035TN00), CXCR2 (#CXCR20TN00), CCR5 (#CCR050TN00) 
and P2Y12R (#P2Y120TN00) obtained from cDNA Resource Center 
(Bloomsburg University, USA). Myc-DDK-tagged expression vectors for 
ATP1A1 (RC201009), ATP1A3 (RC203198) and untagged expression vector 
for ATP1A2 (SC119715) were obtained as lyophilised DNA (OriGene, 
Rockville, MD). ATP1A2 cDNA was amplified using primers 13 and 14 (table 
S2), digested with Sgf1/Mlu1 and ligated into pre-digested pCMV6-Entry. All 
expression vectors were cloned and stored in DH5alpha. All constructs were 
verified by Sanger sequencing. 
 
Heterologous expression and pull-down assays 
HEK293T cells were grown at 37 ºC, 5% CO2 in DMEM Medium supplied with 
10% FBS and 1% PenStrep (all ThermoFisher Scientific, USA). Upon reaching 
70% confluency HA- and Strep-tagged constructs were transiently transfected 
using Lipofectamine 3000 (ThermoFisher Scientific, USA) according to the 
supplier’s recommendation. Cells were lysed after 48 hours with lysis buffer 
(150 mM KCl, 0.5% CHAPS, 50 mM HEPES (pH 7.4)) containing Halt Protease 
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Inhibitor Cocktail (ThermoFisher Scientific, USA). Lysates were centrifuged at 
3000 g for 10 minutes at 4°C. Supernatants were collected and incubated with 
1 U/mL of Avidin to block endogenous biotin for 15 min at 4 °C.  Afterwards 
samples were centrifuged again at 3000 g for 10 minutes at 4 °C. Protein 
concentration was measured by analysing absorbance at 280 nm and set to 5 
mg/mL. Strep-tagged protein was purified from 10 mg total protein using 1 mL 
StrepTactin columns (IBA Life Sciences, Goettingen, Germany). The 
purification procedure was carried out as recommended by the supplier and 
purified protein eluted with 5 mM Desthiobiotin. The eluate was analysed by 
immunoblot and silver-stained SDS PAGE. 
SDS gels were submitted to the Cambridge Centre for Proteomics, University 
of Cambridge. The protein bands were excised, containing proteins reduced, 
alkylated and subsequently digested enzymatically. Samples were analysed by 
reverse-phase HPLC tandem MS. Resulting spectra were analysed using the 
MASCOT database and interpreted using the Uniprot database. 
 
Immunoprecipitation 
HEK293T cells were transiently transfected with HA-tagged constructs. After 
24 hours cells were lysed in CHAPS buffer (150 mM KCl, 0.5% CHAPS, 50 mM 
HEPES (pH 7.4)) containing Halt Protease Inhibitor Cocktail and Phosphatase 
Inhibitor (ThermoFisher Scientific, USA). The lysates were centrifuged for 10 
min at 3000 g at 4 °C. The supernatants were collected and protein 
concentration measured using absorbance at 280 nm. Protein concentration 
was normalized across samples to 1 µg/µL and 200 µg used per 
immunoprecipitation experiment. Protein was precipitated with HA Antibody 
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(CST Technologies #3724) or ATP1A1 Antibody (ThermoFisher Scientific, 
MA3-928). Precipitation was carried out over night at 4 °C under constant 
shaking. IgG Isotype control antibody was used as a control. Protein-Antibody 
complexes were then conjugated to 70 µL Protein A sepharose beads each for 
1 hour at 4 °C under constant shaking. Samples were then washed three times 
with 500 µL of TBST buffer containing 0.05% Tween 20. Protein complexes 
were finally eluted with 50 µL 0.2 M Glycine (pH 2). Eluates were immediately 
neutralized by addition of 5 µL 1 M Tris-HCl (pH 7.5). 4X Laemmli buffer 
containing 10 % 2-Mercaptoethanol was added to eluates and lysates prior 
SDS-PAGE and Immunoblot analysis. 
 
Gene silencing 
siRNA was transfected using Lipofectamine 2000 (ThermoFisher Scientific) 
according to the manufacturer’s protocol for experiments involving Caco2 cells. 
THP1 and primary BMDMs were silenced using Amaxa Nucleofector Kit (Lonza 
VPA-1109 and VPA-1103) as per the manufacturer’s protocol. 
 
Rubidium Uptake Assay 
Rubidium uptake was determined as described in Figueroa et al. (91), 
Specifically, cells were seeded in 6 well plates and allowed to attach overnight 
in normal culture medium. Immediately prior to the assay, cells were washed 
three times with 1 ml of rubidium assay buffer (130 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 0.5 mM NaH2PO4, 10 mM d-glucose, 12 mM NaHCO3, 
10 mM HEPES; pH 7.4). Cells were then incubated for 1 or 2 hours at 37 °C in 
rubidium assay buffer containing 270 µM RbCl. Incubation was carried out with 
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and without 1 mM Ouabain. Subsequently, cells were washed three times in 
rubidium buffer and scraped into 1 mL of ultrapure water. 10 µL of 100 ppB 
Cerium was added as an internal control. Afterwards, 1.4 g of Nitric Acid 70 % 
(SigmaAldrich #225711) was added and samples boiled at 100 °C for 30 min. 
Then 250 µL H2O2 (SigmaAldrich #95321) was added and samples boiled 
again at 100 °C for 30 min. As a last step, samples were diluted 1:10 with nitric 
acid 1 % prior to analysis by ICP-MS. 85Rb+ concentrations measured were 
normalized to sulfur (S) concentration and the internal Cerium control.  
 
Seahorse extracellular flux analysis 
Cells were seeded into 96 well XFe Seahorse plates (Agilent, USA) in normal 
culture medium. 1 hour prior to the start of extracellular flux measurements, the 
medium was changed to Agilent Seahorse XF Base Medium (103334-100) 
supplemented with 1 mM L-glutamine (ThermoFisher Scientific, USA) and 10 
mM D-glucose (SigmaAldrich, UK). The pH of the medium was set to 7.4 after 
warming to 37 ºC. OCR and ECAR were measured using the XFe96 Seahorse 
extracellular flux analyser (Agilent, USA) over the course of 2 hours. Oligomycin 
(1 µM), FCCP (1.5 µM) and Rotenone/Antimycin A (both 1 µM) (all Sigma 
Aldrich, UK) were injected sequentially to allow assessment of respiratory chain 
functionality. Glycolytic function was measured in a separate protocol. Cells 
were incubated in seahorse assay medium without glucose. Glycolysis was 
assessed through measurement of ECAR after sequential injections with D-
glucose (10 mM), Oligomycin (1 µM) and 2-deoxyglucose (100 mM) 
(SigmaAldrich, UK). Spare respiratory capacity (SRC) was computed as the 
difference between basal OCR and maximal OCR after FCCP injection. 
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Maximal glycolytic capacity was computed as the difference between ECAR 
after injection with D-glucose and ECAR after injection with Oligomycin. 
 
Glucose uptake assay 
The Glucose Uptake-Glo Assay (Promega, USA) was used according to the 
supplier’s recommendation. Briefly, BMDMs were seeded into in white 96 well 
plates (Nunc, Denmark) at a cell density of 5 x104 cells per well and polarised 
as described above. Cells were washed once with PBS and then incubated with 
PBS containing 1 mM 2-deoxyglucose (2-DG) for the given time points (10 – 
60 min). The reaction was stopped with stop buffer and immediately after this 
pH was neutralized with neutralization buffer. The detection reagent for 2-deoxy 
glucose-6-phosphate (2DG6P) was added to the wells. After incubation for 1 
hour, luminescence (Centro LB 690 Luminometer, Berthold) was measured 
using 0.3 second integration every 2 minutes for 15 minutes. A standard curve 
of 2DG6P was used to extrapolate the concentration of 2DG6P in the sample. 
 
Membrane potential 
Cell membrane potential was measured by incubating cells with 1.9 µM 
DiBAC4(3) (molecular probes, B438) for 20 minutes. A fluorescent plate reader 
was then used to excite the dye at 493nm and measure emission at 516nm. 
Mitochondrial membrane potential was measured by incubating cells with 10 
µg/mL JC-1 (molecular probes T3168) for 10 minutes at 37 C before measuring 
emission at 530nm and 535nm upon excitation at 485nm and 535nm 
respectively. 
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Antibodies, plasmids and reagents 
Antibodies directed against HA (3724), ATP1A1 phospho-Ser16 (4020S), -
actin (4970S), polyclonal normal IgG (2729S), AMPK (2532), AMPK phospho-
Thr172 (2535), pan Akt (4685S), Akt phospho-Thr308 (5056S), Akt phospho-
Ser473 (4058), Src (2109S), Src phospho-Tyr416 (2101), EGFR (4267), EGFR 
phospho-Tyr1068 (8543S), p44/42 MAPK (Erk1/2) (4695), p44/42 MAPK 
(Erk1/2) phospho-Thr202/Tyr204 (4094S) and anti-Ki-67 (11882) were purchased 
from Cell Signaling Technology. Antibodies directed against c-myc-tag 
(MA1980) and ATP1A1 (MA3-928) were purchased from Thermo Fisher 
Scientific. The antibody directed against mouse normal IgG (sc-2025) was 
purchased from Santa Cruz Biotechnology. Pepducins and pNaktide were 
custom synthesised by Peptide 2.0 Inc. 
The pEXPR-IBA 103 Strep-tag plasmid (2-3503-000) was purchased from IBA 
Life Sciences. HA tagged plasmids (GPR035TN00, CXCR20TN00 and 
CCR050TN00) were purchased from the cDNA Resource Centre. Plasmids for 
ATP1A1 (RC201009), ATP1A2 (SC119715) and ATP1A3 (RC203198) were 
purchased from Origene. mVenusN1 (27793) and mCeruleanN1 (27795) were 
purchased from Addgene. The HPSI0114i-kolf_2 (KOLF-2) (ECACC 
77650100) iPSC cell line has previously established by the Wellcome Trust 
Sanger Institute. Other cell lines were purchased from ATCC. 
 
Statistical analysis 
All statistical analysis was performed using Prism 7 (GraphPad) software. The 
statistical tests used in each experiment are described in the respective figure 
legends. 
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Supplementary Materials 
 
Fig. S1. KYNA and CXCL17 induce RhoA and Rac1 signaling in Gpr35+/+ 
BMDMs.  
Fig. S2. siRNA knock-down of GPR35, CCR5, CB2R, b-AdR, and LPAR2 
Fig. S3. Lack of GPR35 decreases cellular respiration in M1 BMDMs.  
Fig. S4. GPR35 pepducins induce migration and Ca2+ release in Gpr35+/+ 
BMDMs.  
Table S1. Proteins identified in GPR35 pulldown samples.  
Table S2. Oligonucleotide sequences.  
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Figures, legends and tables 
Figure 1. GPR35 deficiency re-sets resting cytoplasmic Ca2+ levels and 
GPR35 interacts with the -chain of Na/K-ATPase.  
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A, Intracellular Ca2+ release in BMDMs at basal level (control) and after 
stimulation with CXCL17 (200 ng/mL), zaprinast (10 µM) or KYNA (300 µM); 
n=3 mice/group. B, Cyclic AMP (cAMP) production in BMDMs after stimulation 
with CXCL17 (200 ng/mL) or KYNA (300 µM); n=3 mice/group. C, Dose 
dependent inositol trisphosphate (IP3) generation in BMDMs after stimulation 
with CXCL17 (0.2 - 200 ng/mL) or KYNA (0.1 nM - 100 µM) for 20 min; n=3 
mice/group. D, Directed migration (chemotaxis) of BMDMs towards different 
concentrations of CXCL17 and KYNA expressed as the chemotaxis index of 
stimulated compared to unstimulated cells; n=3 mice/group. E, Undirected 
migration of MEFs expressed as distance migrated into membrane; n=7 
independent experiments for Gpr35+/+ and n=8 independent experiments for 
Gpr35-/-/group (we have used 3 Gpr35+/+ and 3 Gpr35-/- clones). F, Migratory 
distance of MEFs towards KYNA and Zaprinast; n=3 clones. G, Undirected 
migration of THP1 cells transfected with either GPR35 siRNA or scrambled 
siRNA (scrambled ctrl); n=6 independent experiments/group. Data are shown 
as mean ± s.e.m. Statistical significance calculated by Mann Whitney U test 
after Kruskal Wallis one-way ANOVA. H, Immunoprecipitates of HA tagged 
GPCRs probed for ATP1A1 (upper panel). Immunoprecipitates of ATP1A1 
probed for HA (middle panel). Immunopreciptation using normal IgG antibody 
(IgG) used as a control. Western blot of HA-tagged GPCRs in whole cell 
lysates shown below. n=3 independent experiments I, Immunoprecipitates of 
HA-tagged GPR35108T or GPR35108M variant probed for myc-tagged ATP1A 
isoforms. Western Blot of myc-tagged ATP1A isoforms in whole cell lysates 
shown above (upper two panels). Immunoprecipitates of myc-tagged ATP1A 
isoforms (ATPA1-3) probed for HA. Western Blot of HA-tagged GPR35108T or 
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GPR35108M variant in whole cell lysates shown above (lower two panels). 
Immunopreciptation using normal IgG antibody (IgG) used as a control. 
Arrows indicate the relevant band. n=3 independent experiments J, 
Fluorescent microscopy of ATP1A1-Venus (green) and Cerulean tagged 
GPR35108T or GPR35108M variant (red) co-expressed in HEK293 cells. 
Cerulean tagged CCR5 (red) used as a control. Scale bar, 5 µm. K, 
Fluorescence resonance energy transfer (FRET) efficiency measuring 
proximity of fluorescent-labelled GPR35108T or GPR35108M variant and 
ATP1A1 co-expressed in HEK293 cells. Fluorescent-labelled CCR5 and 
CXCR2 used as a control. GPR35 homo dimers used as a positive control. 
Data points represents individual acceptor photo bleaching events. n=6 
events from 3 independent experiments for GPR35 homodimers and CCR5 
and CXCR2 control, n=9 events from 3 independent experiments for 
GPR38108M and GPR35 108T. All data represented as mean ± s.e.m. 
Statistical significance was calculated by two-way ANOVA followed by post-
hoc comparison of means, ** (p<0.01). 
 
Figure 2. GPR35 sets resting intracellular Ca2+ by promoting Na/K-
ATPase function. 
A, Intracellular 85Rb+ concentration (nM) measured by ICP-MS in M0, M1 and 
M2 BMDMs (n=3 mice/group) and B, Caco2 cells transfected with GPR35 
siRNA or control siRNA (ctrl) (n=3 independent experiments/group), after 2 
hours of incubation in Rb85+ containing media in the absence or presence of 1 
mM ouabain. C, Plasma membrane potential (Δψp) in M0 BMDMs. Δψp is 
expressed as relative change (%) of fluorescent units (RFU) at 516 nm. n=18 
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cells from 3 mice/group. d-e, Intracellular Ca2+ release in BMDMs under 
baseline conditions and after stimulation with ouabain (1 mM), MIP-1  (10 
nM), RANTES (10 nM), isoproterenol (ISOP) (1 µM), andanamide (AEA) (10 
µg/mL) or lysophosphatidic acid (LPA) (1 µM); n=3 mice/group. Arrow 
represents time point at which stimuli were injected. f, Intracellular Ca2+ 
release at basal level and after stimulation with MIP-1  (10 nM), RANTES (10 
nM), isoproterenol (ISOP) (1 µM), andanamide (AEA) (10 µg/mL) or 
lysophosphatidic acid (LPA) (1 µM) in BMDMs of wild type mice transfected 
with siRNA targeting the corresponding cognate receptor (grey) or control 
siRNA (ctrl) (red); n=3 mice/group. Arrow represents time point at which 
stimuli were injected. g, Immunofluorescence detection of ATP1A1 (red) 
showing equal expression and localization on the cell membrane of BMDMs 
of Gpr35+/+ and Gpr35–/– mice. Nuclei stained with DAPI (blue). Scale bar, 
25µm. Representative images (left panels); n=3 mice per group. 
Quantification of membrane-bound (non-permeabilized) and cytoplasmic 
(permeabilized) ATP1A1 of BMDMs by FACS (right panels); n=3 mice/group. 
h-i, Western blot detection of ATP1A1 and p-ATP1A1 (Ser16) in BMDMs and 
colon; n=3 mice j, Intracellular 85Rb+ concentration (nM) measured via ICP-
MS after 2 hours of incubation in 85Rb+ containing media in the absence or 
presence of 1 mM ouabain in human iPSC-derived M0 macrophages 
comparing GPR35108T (red), (n=6 sets of cells) and GPR35108M variant (black), 
(n=9 sets of cells); k, Basal intracellular calcium level in human iPSC derived 
M0 macrophages. n=7 individual experiments per group (3 technical 
replicates/individual experiment). l, Undirected migration of human iPSC 
derived M0 macrophages, n=7 individual experiments/group (2 technical 
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replicates/individual experiment). m, Western blot of ATP1A1 in iPSC derived 
M0 macrophages. n=3 independent experiments. All data represented as 
mean ± s.e.m. Statistical significance was calculated by two-tailed Student’s t 
test using individual data points for 85Rb+ uptake and membrane potential 
assays and Mann Whitney U after Kruskal Wallis for intracellular Ca2+ 
measurements, * (p<0.05), ** (p<0.01). 
 
Figure 3. GPR35 controls macrophage and intestinal epithelial cell 
metabolism. 
A, Glucose uptake in M0, M1 and M2 BMDMs in the absence or presence of 
ouabain (1 mM). Glucose uptake expressed as intracellular 2-deoxy-D-
glucose-6-phosphate (2DG6P) concentration detected per cell; n=3 
mice/group. B, Lactate production measured in M1 and M2 BMDMs; n=3 
mice/group. C, ECAR measured during sequential injection of oligomycin (O) 
and 2-deoxyglucose (2-DG) in Caco2 cells transfected with control (ctrl) 
siRNA (red) or GPR35 siRNA (blue). Bar chart shows basal ECAR; n=3 
mice/group. D, Cellular respiration measured as basal and maximal oxygen 
consumption rate (OCR) during sequential treatment with oligomycin (O), 
FCCP (F) and antimycin/rotenone (A/R) in M0 and M2 BMDMs. Bar chart 
indicates basal and maximal OCR after FCCP injection; n=3 mice/group. E, 
Basal and maximal OCR measured during sequential treatment with 
oligomycin (O), FCCP (F) and antimycin/rotenone (A/R) in Caco2 cells 
transfected with either control (ctrl) siRNA (red) or GPR35 siRNA (blue). Bar 
chart indicates basal and maximal OCR after FCCP stimulation; n=3 
independent experiments/group. F, Mitochondrial membrane potential (ΔΨm ) 
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in M0, M1 and M2 BMDMs in the absence or presence of 1 mM ouabain. 
Depolarisation with 1 µM FCCP used as a control. ΔΨm expressed as relative 
fluorescent units (RFU) at 590 nm; n=6 mice/group. G, Glucose uptake in 
human iPSC derived M0 macrophages in the absence or presence of ouabain 
(1 mM); n=3 independent experiments. H, Basal ECAR measured in human 
iPSC derived M0 macrophages; n=8 sets of cells/group. I, Lactate production 
in human iPSC derived M0 macrophages; n=3-4 sets of cells/group. J, Basal 
and maximal OCR during sequential treatment with oligomycin (O), FCCP (F) 
and antimycin/rotenone (A/R) in iPSC-derived human macrophages 
homozygous for the GPR35108T (red) or GPR35T108M (black) alleles. Bar chart 
indicates basal and maximal OCR after FCCP stimulation; n=8 sets of 
cells/group. All data represented as mean ± s.e.m. Statistical significance was 
calculated by two-tailed Student’s t test using individual data points, * 
(p<0.05), ** (p<0.01). 
 
Figure 4: GPR35 modulates Na/K ATPase dependent signaling. 
A-C, Western Blot detection of total Src, p-Src (Tyr416), p-Erk1/2 
(Thr202/Tyr204), pan-Akt, p-Akt (Thr308) and p-Akt (Ser473) in BMDMs. n=3 
mice/genotype. D-E, Western Blot detection of total Src, p-Src (Tyr416), pan-
Akt, p-Akt (Thr308) and p-Akt (Ser473) in BMDMs with or without treatment with 
pNaKtide (1 μM). n=3 mice. f, Detection of total AMPK and p-AMPK Thr172 in 
BMDMs. n=3 mice/genotype. G-I, Western Blot detection of total Src, p-Src 
(Tyr416), pan-Akt, p-Akt (Thr308), p-Akt (Ser473), EGFR and p-EGFR (Tyr1068) in 
Caco2 cells transfected with either control (ctrl) siRNA or GPR35 siRNA. n=3 
independent experiments/group. J-K, Western blot detection of total Src, p-
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Src (Tyr416), p-Erk1/2 (Thr202/Tyr204), total Erk1/2, p-Akt (Thr308) and pan-Akt in 
human iPSC derived M0 macrophages (J) and human iPSC derived 
fibroblasts (K). n=3 independent experiments/group. L, Western blot detection 
of p-Src (Tyr416) and total Src in human iPSC derived M0 macrophages in the 
absence (control) or presence of treatment with pNaktide (1 μM). n=3 
independent experiments/group. 
 
Figure 5. GPR35 maintains intestinal epithelial cell turnover under 
homeostatic conditions. 
a, Immunohistochemistry of p-Src (Tyr416) in intestinal sections from Gpr35+/+ 
and Gpr35–/–mice. Representative images of 6 mice per group. Scale bars 
represent 100 µm. b, Immunohistochemistry of BrdU incorporation after a 24 
hour pulse in intestinal sections from Gpr35+/+ and Gpr35–/– mice. 
Representative images (left panel). Quantification of cells staining positive for 
BrdU (right panel). Each data point represents one crypt villus axis from 3 
individual mice per group. c, Quantification of cells staining positive for Ki-67 
using immunohistochemistry in intestinal sections from Gpr35+/+ and Gpr35–/– 
mice. Each data point represents one crypt villus axis; n=3 mice per group. d, 
Representative immunofluorescent images of colonic organoid cultures 
stained with EdU (green) for proliferative cells (left panel). Quantification of 
EdU positive cells in Gpr35+/+ and Gpr35–/– organoids (right panel). Each data 
point represents one organoid. Scale bars, 250 μm; n=3 mice per group. e, 
Representative images showing immunohistochemistry of BrdU incorporation 
in intestinal sections of Gpr35+/+ and Gpr35–/– mice after treatment with 
pNaKtide. Scale bars 100 μm (left panel). Timeline of pNaKtide and BrdU 
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injections shown below. Quantification of cells staining positive for BrdU using 
immunohistochemistry (right panel). Each data point represents one crypt 
villus axis; n=3 mice per group. All data represented as mean ± s.e.m. 
Statistical significance was calculated by Mann Whitney U after Kruskal 
Wallis. 
 
Figure 6: Loss of GPR35 protects from intestinal tumorigenesis. 
A, Haemotoxylin and eosin (H&E) stain of ileal swiss rolls from 
Gpr35+/+;Apcmin and Gpr35–/–;Apcmin mice (left). Total number of intestinal 
tumors in 15-week-old Gpr35+/+;Apcmin (red, n=8), Gpr35+/–;Apcmin (grey, 
n=19) and Gpr35–/–;Apcmin (blue, n=17) littermates (right). Scale bar, 5 mm. B, 
Gpr35 mRNA expression of tumor tissue compared to healthy intestinal 
tissue. n=15 tissue samples/group. C, mRNA expression in Gpr35+/+ mice 
compared to Gpr35 ΔIEC mice, n=3 mice/group.  D, Total number of intestinal 
tumors in 15-week-old Gpr35WT;Apcmin (red, n=22) and Gpr35ΔIEC;Apcmin 
(blue, n=14) littermates. E, Quantification of cells staining positive for Ki-67 
using immunohistochemistry in intestinal sections of 15-week-old Gpr35 
WT;Apcmin (n=12) and Gpr35 ΔIEC;Apcmin (n=12) littermates. F, Number of 
tumors in the large intestine of Gpr35+/+ (red, n=19) and Gpr35–/– (blue, n=16) 
mice in the AOM-DSS model. All data represented as mean ± s.e.m. 
Statistical significance was calculated using the Mann Whitney U test after 
Kruskal Wallis one-way ANOVA. 
  
Figure 7: Pharmacological targeting of GPR35 selectively modulates 
receptor activity and decreases tumor burden in colitis-associated cancer 
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A, Structural model of GPR35 focused on the second intracellular loop (left 
panel). The position of the T108M variant is marked in pink and the DRY motif 
is marked in purple. The g35-i2 pepducin targeted region is marked in red (i2-
loop). The amino acid sequence of g35-i2 (middle panel) and g35-i3 (right 
panel) pepducins mapped to human and murine GPR35 i2 and i3 loops. B, 
Dose dependent IP3 generation in BMDMs after stimulation with g35-i2 
pepducin; n=3 mice/group. C, cAMP production in BMDMs after stimulation with 
g35-i3 pepducin; n=3 mice/group. D, Activated Rac-1 and Rho A levels in 
BMDMs after stimulation g35-i3 pepducin; n=3 mice/group. E, Intracellular Ca2+ 
release in BMDMs basally and after stimulation with g35-i2 (closed circles) or 
g35-i3 pepducin (open circles); n=3 mice/group. F, Chemotaxis of THP-1 cells 
transfected with either GPR35 siRNA Rac-1 siRNA (ctrl) stimulated with g35-i2 
or g35-i3 pepducin. Untreated cells are used as a control. G, Directed migration 
of THP-1 cells transfected with either GPR35 siRNA (blue) or control siRNA 
(ctrl) (red) towards zaprinast (10 µM), KYNA (300 µM) or CXCL17 (200 ng/mL) 
in the presence (closed bars) or absence (open bars) of g35-i2 pepducin. n=3 
independent experiments/group. H, Intracellular 85Rb+ concentration (nM) 
measured by ICP-MS in the absence or presence of 1 mM ouabain in BMDMs 
after 1 hour of incubation in 85Rb+ containing media in the presence of g35-i2 
pepducin, KYNA (300 µM) or zaprinast (10 µM); n=3 mice/group. I, 
Representative images showing immunohistochemistry of BrdU incorporation 
in intestinal sections of Gpr35+/+ and Gpr35–/– mice after treatment with g35-i2 
(5 mg/kg) or g35-i3 (5mg/kg) pepducins (left panel). Quantification of cells 
staining positive for BrdU using immunohistochemistry (right panel). Each data 
point represents one crypt villus axis; n=3 mice per group. Scale bar represents 
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100µm. J, Number of colonic tumors in vehicle treated (n=7) or g35-i2 pepducin 
treated (n=8) Gpr35+/+ (red) mice compared to vehicle treated (n=8) or g35-i2 
pepducin treated (n=8) Gpr35–/– (blue) mice in the AOM-DSS model. All data 
represented as mean ± s.e.m. Statistical significance was calculated using 
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Fig. S1. KYNA and CXCL17 induce RhoA and Rac1 signaling in Gpr35+/+ 
BMDMs. a, Activated RhoA and Rac-1 levels in BMDMs from Gpr35+/+ (red) 
and Gpr35–/– (blue) mice under basal conditions and after stimulation with 
KYNA (300 µM) or CXCL17 (200 ng/mL); n=3 mice/group. b, 
Immunofluorescent staining of actin stress fibres in murine embryonic 
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conditions or stimulation with KYNA (300 µM) or CXCL17 (200 ng/mL). 
Representative of 3 mice/group. Scale bar, 100µm.  
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Fig. S2. siRNA knock-down of GPR35, CCR5, CB2R, b-AdR, and LPAR2 
a. Relative mRNA levels of GPR35 in Caco-2 cells measured by qRT-PCR and 
normalized to ACTB (E-actin); n=3 independent experiments. b. Protein levels 
of CCR5, CB2R, E-AdR and LPAR2 after siRNA knockdown in murine BMDMs. 
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Fig. S3. Lack of GPR35 decreases cellular respiration in M1 BMDMs. 
Cellular respiration measured as basal and maximal oxygen consumption rate 
(OCR) during sequential treatment with oligomycin (O), FCCP (F) and 
antimycin/rotenone (A/R) in M1 macrophages generated from BMDMs of 
Gpr35+/+ (red) and Gpr35–/– (blue) mice; n=3 mice per group. The 
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Fig. S4. GPR35 pepducins induce migration and Ca2+ release in Gpr35+/+ 
BMDMs. a. Pepducins were designed to interfere with the i1-, i2- and i3 loop of 
human and murine GPR35. b. Pepducins were tested for specificity by 
chemotaxis assays and Ca2+ release in Gpr35+/+ and Gpr35-/- BMDMs. n=8 
mice per group for chemotaxis experiments and n=6 mice per group for Ca2+ 
measurements. Statistical significance was calculated by Mann Whitney U test 
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Protein UniprotKB kDA No. of peptides Coverage in % 













Calnexin (CANX) P27824 72 49 37 39 38 34 35 
Lamin-B1 (LMNB1) P20700 66 45 21 42 38 30 43 
Sodium/potassium-transporting ATPase subunit alpha-1 
(ATP1A1) P05023 113 31 20 50 31 23 37 
Heterogeneous nuclear ribonucleoprotein M (HNRNPM) P52272 78 33 29 2 29 32 3 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 (RPN1) Q6IBR0 69 30 18 39 34 33 41 
Clathrin heavy chain (CLTC) A0A087WVQ6 192 34 25 13 26 19 10 
Cytoskeleton-associated protein 4 (CKAP4) A0A024RBH2 66 21 13 26 30 30 50 
T-complex protein 1 subunit delta (CCT4) P50991 58 26 16 22 42 34 39 
DNA-dependent protein kinase catalytic subunit (PRKDC) P78527 469 27 17 7 8 5 2 
4F2 cell-surface antigen heavy chain(SLC3A2) F5GZS6 65 21 17 33 33 29 31 
Cytoplasmic dynein 1 heavy chain 1 (DYNC1H1) DYHC1 532 25 10 2 7 2 0 
Chaperonin containing TCP1, subunit 6A (Zeta 1) (CCT6A) A0A024RDL1 58 22 21 5 30 24 14 
Chaperonin containing TCP1, subunit 8 (Theta) variant Q53HU0 60 36 21 3 55 28 7 
Exportin-2 (CSE1L) P55060 108 23 19 8 25 21 9 
T-complex protein 1 subunit gamma Q59H77 64 31 18 3 30 25 7 
Thymopoietin (TMPO) A0A024RBE7 51 24 17 15 50 38 43 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
(ATP2A2) P16615 115 8 6 26 9 6 28 
Matrin-3 (MATR3) A8MXP9 100 23 15 2 26 16 3 
Karyopherin (importin) beta 1 (KPNB1) B2RBR9 97 29 16 4 31 22 4 
C-1-tetrahydrofolate synthase (MTHFD1) F5H2F4 111 25 11 2 27 14 2 
Bifunctional glutamate/proline--tRNA ligase (EPRS) SYEP 171 16 14 4 12 11 3 
Chaperonin containing TCP1, subunit 7 Q53HV2 59 20 15 4 39 30 9 
Isoleucyl-tRNA synthetase Q59G75 146 20 11 3 17 10 2 
Heterogeneous nuclear ribonucleoprotein H (HNRNPH1) G8JLB6 51 16 16 4 31 32 12 
Transmembrane emp24-like trafficking protein 10( TMED10) A0A024R6I3 25 13 10 15 43 41 43 
Transferrin receptor protein 1 (TFRC) TFR1 85 13 10 14 21 16 22 
Transmembrane emp24 protein transport domain containing 9 
(TMED9) A0A024R7M0 27 8 5 12 39 34 39 
H.sapiens ras-related Hrab1A protein(cRAB1A) Q5U0I6 23 13 11 9 52 60 50 
PGRMC1 protein (PGRMC1) Q6IB11 22 9 9 15 35 36 48 
D-3-phosphoglycerate dehydrogenase (PHGDH) SERA 57 15 9 5 28 21 13 
         
G-protein coupled receptor 35 (GPR35) Q9HC97 37 35 40 36 34 34 41 
 
108T: C terminal GPR35-Strep; 108M: C terminal GPR35-Strep T108M variant; 108T*: C-terminal GPR35-HA. 
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Table S1. Proteins identified in GPR35 pulldown samples. The table shows 
proteins sorted according to number of mapped peptides in the sample. 
Proteins that were identified in samples from tag only- or mock-transfected 
cells were omitted. 
Table S2. Oligonucleotide sequences 
No Name Sequence 
 Cloning Oligonucleotides  
1 gpr35a_Ctag_EcoRI_fwd CGGAATTCAATGGCCCTACAACACCTGTGG 
2 gpr35a_Ctag_BamHI_rev GCGGATCCGGCGAGGGTCACGCACAGA 
3 hGPR35_T108M_fwd GCATCAGCCTGGTCATGGCCATCGC 
4 hGPR35_T108M_rev GCGATGGCCATGACCAGGCTGATGC 
5 gpr35a_Ctag2_EcoRI_fwd CGGAATTCATGAATGGCACCTACAACACCTGTG 
6 gpr35a_Ctag2_BamHI_rev CGGGATCCTTGGCGAGGGTCACGCACA 
7 nXhoI_atp1a1_fwd GCCTCGAGATGGGGAAGGGGGTTGGA 
8 atp1a1_Ctag2_XmaI_rev GCCCCGGGGGATAGTAGGTTTCCTTCTCCACCCAG 
9 XhoI_CXCR2_fwd CGCTCGAGATGGAAGATTTTAACATG 
10 HindIII_CXCR2_rev CGAAGCTTGAGAGTAGTGGAAGTGTGC 
11 XhoI_CCR5_fwd CGCTCGAGATGGATTATCAAGTGTC 
12 HindIII_CCR5_rev CGAAGCTTCAAGCCCACAGATATTT 
13 AsiSI_atp1a2_fwd CGGCGATCGCATGGGCCGTGGGGCTG 
14 MluI_atp1a2_rev CGACGCGTGTAGTATGTCTCCTTCTCCACCCA 
 qPCR Oligonucleotides  
14 qmgpr35_fwd AAATCCCCACCTTTCAGCACA 
15 qmgpr35_rev CATGGTCCTAGGGCTCATCTG 
16 qhgpr35_fwd GCTCACCCCAGCTTCACTTC 
17 qhpr35_rev TAGGTGCCATTCATGGTCCTGC 
18 Human betaActin Qrev GGGGTACTTCAGGGTGAGGA 
19 Human betaActin Qfwd GATGCCCCCCGGGCCGTCTT 
20 mBeta Actin forward GCCCTGAGGCTCTTTTCCAG 
21 mBeta Actin reverse TGCCACAGGATTCCATACCC 
 CRISPR oligonucleotides  
22 guideRNA1_rs3749171 CCTGGTCACGGCCATCGCCG 
23 guideRNA2_rs3749171 CACATAGCGGTCCACGGCGA 
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24 Cloneselection_1_Fwd GGCTTCTACGCCTACTTGGG 







 siRNA sequences  
28 Human GPR35 ThermoFisher Scientific siRNA ID: s6063 
29 Mouse CCR5 Dharmacon siGENOME SMARTpool Cat# M-058452-01 
30 Mouse CB2R Dharmacon siGENOME SMARTpool Cat# D-062503-01 
31 Mouse E-AdR Dharmacon siGENOME SMARTpool Cat# D-042042-01 




















































GPR35 CXCR2 CCR5  P2Y12 Mock
IP IgG IP IgG IP IgG IP IgG IP IgG
250 kD -
 -150 kD   -
150 kD   -
50 kD  -







37 kD  -







A1 A2 A3 A1 A2 A3
IP IgG
ATP1  myc-Tag ATP1  myc-Tag
Mock
IP IgG IP IgG IP IgG IP IgG IP IgG IP IgG














































p = 0.02 p = 0.03
MEF

























































































































































































































































































































































0 5 10 2015
Minutes
0 5 10 2015
Minutes
0 5 10 2015
Minutes
0 5 10 2015
Minutes
0 5 10 2015
Minutes
0 5 10 2015
Minutes
Minutes Minutes






















































































































p = 0.002 p = 0.003 p = 0.0001p = 0.003p = 0.0001




























































0 20 40 60
Minutes
0 20 40 60
Minutes


















































































































18 44 70 96
Minutes
D
















































































































































































































































































































































































































































































































p > 0.99  p = 0.0004








































































































































































































untreated g35-i2 KYNA zaprinast














































































se p = 0.002
p = 0.034 p = 0.79
p = 0.504
Human GPR35       TAIAVDRYVAV         RHPLRARGLRSP    RQAAA
Murine GPR35 TAIAVDRYVAV         RHPLRARGLRSP     RQAAA
G35-i2 pal-VAV         RHPLRARGL
i2-loop TM4TM3
SLKWTALAQR            PPTD                      VGQAE
LQVVTVLSRR PAAD                      VGQAE
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